142 unknown. 142 Phase 2, 53 Phase 1, 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 142 | Unknown 142 |
| Phase 1 | 53 | Unknown 53 |
| Phase 3 | 13 | Unknown 13 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 68 | 2023-10-01 | 2023-10-10 |
| Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 20 | 2023-09-10 | 2023-11-01 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia Anti-CD56 CAR T - Extranodal NK T Cell Lymphoma, NK-Cell Leukemia | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2023-05-01 | 2023-07-12 |
| Acute Concussion and Melatonin Melatonin 3 MG, Placebo - Concussion, Mild, Concussion, Brain | Phase 2 | Unknown | Children's National Research Institute | 254 | 2023-03-01 | 2024-02-07 |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) Petiveria Alliacea Preparation, Placebo - Neoplasm, Stomach, Gastric Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Hospital Universitario San Ignacio | 82 | 2022-12-15 | 2022-10-19 |
| Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL cytarabine+thiotepa+ fludarabine + busulfan - Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 70 | 2022-10-23 | 2022-10-28 |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase I, Phase II - Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 / Phase 2 | Unknown | KK Women's and Children's Hospital | 48 | 2022-07-18 | 2023-03-09 |
| Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL Orelabrutinib, Obinutuzumab, Fludarabine - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 25 | 2022-04-15 | 2022-04-19 |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, Zanubrutinib, bendamustine, rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 63 | 2022-03-22 | 2022-03-31 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT VEN+AZA+Modified BUCY - Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 55 | 2022-01-20 | 2023-04-12 |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL Cladribine, Fludarabine - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 32 | 2022-01-01 | 2022-10-13 |
| Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL PTG-CARCIK-CD19 - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 35 | 2021-12-01 | 2023-05-06 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL Navitoclax, Venetoclax - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Israeli Medical Association | 48 | 2021-10-01 | 2021-09-23 |
Showing 20 of 142. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (87) · Leukemia, Lymphocytic, Chronic, B-Cell (48) · Lymphoma (33) · Lymphoma, Large B-Cell, Diffuse (25) · Lymphoma, Non-Hodgkin (24) · Leukemia (23) · Leukemia, Myeloid, Acute (22) · Lymphoma, Follicular (22) · Burkitt Lymphoma (18) · Lymphoma, Mantle-Cell (18) · Lymphoma, B-Cell (14) · Myelodysplastic Syndromes (14) · Leukemia, B-Cell (13) · Lymphoma, B-Cell, Marginal Zone (13) · Multiple Myeloma (13)
Hematologic Diseases (142) · Hemic and Lymphatic Diseases (142) · Immune System Diseases (142) · Immunoproliferative Disorders (142) · Lymphatic Diseases (142) · Lymphoproliferative Disorders (142) · Neoplasms by Histologic Type (142) · Neoplasms (140) · Leukemia (119) · Pathologic Processes (62) · Pathological Conditions, Signs and Symptoms (62) · Disease Attributes (60) · Chronic Disease (54) · Leukemia, B-Cell (46)
Cyclophosphamide (23) · Cytarabine (15) · Methotrexate (13) · Vincristine (11) · Dexamethasone (10) · Etoposide (8) · Radiotherapy (8) · Busulfan (7) · Immunotherapy, Adoptive (7) · Rituximab (7) · fludarabine (7) · Antigens, CD19 (6) · Doxorubicin (6) · Mercaptopurine (6) · Prednisone (6)
Chinese PLA General Hospital (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · Nanfang Hospital, Southern Medical University (5) · Chongqing Precision Biotech Co., Ltd (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (3) · Sheba Medical Center (3) · Sichuan University (3) · The First Affiliated Hospital of Soochow University (3) · Wuhan Sian Medical Technology Co., Ltd (3) · Auxilio Mutuo Cancer Center (2) · Chronic Lymphocytic Leukemia Research Consortium (2) · Colorado Blood Cancer Institute (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2)
China (55) · United States (23) · Italy (9) · France (7) · Germany (7) · Canada (5) · Israel (5) · South Korea (5) · Belgium (3) · Mexico (3) · Russia (3) · United Kingdom (3) · Poland (2) · Puerto Rico (2) · Singapore (2)
Cheng Qian, PhD (4) · David G. Savage, MD (2) · Eucario Leon Rodriguez, M.D. (2) · Fernando Cabanillas, MD (2) · Lin Yang, Ph.D. (2) · Monica M Rivera Franco, M.D.,MSc (2) · Qifa Liu, MD (2) · Sanbin Wang, MD (2) · YU HU, M.D., Ph.D (2) · A. Pession (1) · Amir Ali Hamidieh, MD (1) · Andrea Velardi, MD, PhD (1) · Anne Lennard (1) · Anthony D Ho, Ph.D., Prof. (1) · Arnon Nagler, MD (1)
PMID 34515338, PMID 28054442, PMID 40195173, PMID 41671463, PMID 11675328, PMID 15107815, PMID 16155013, PMID 16564913, PMID 17366834, PMID 18358930, PMID 20371346, PMID 20959411, PMID 21220611, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22086414, PMID 22265847, PMID 22323480, PMID 22331940, PMID 22589701, PMID 23140366, PMID 23244073, PMID 24311149, PMID 24475787, PMID 24497570, PMID 24641416, PMID 25444722, PMID 25621950, PMID 25631767, PMID 25682597, PMID 25805929, PMID 25983002, PMID 26687796, PMID 26819050, PMID 27347147, PMID 27579615, PMID 27916294, PMID 28161329, PMID 28412099, PMID 28415728, PMID 29263894, PMID 29506548, PMID 30104718, PMID 30187944, PMID 30696950, PMID 30843659, PMID 31208944, PMID 31409768
2005 (1), 2014 (1), 2016 (1)